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Abstract
Background: Published data on the existence and magnitude of extended spectrum beta-lactamase (ESBL)
production in urinary pathogens in local setting is limited. The aim of the present study was to determine the
prevalence of antimicrobial resistance and ESBL production among Escherichia coli and Klebsiella spp from urine
samples in a tertiary hospital. This was a cross sectional study conducted at Muhimbili National Hospital in Dar es
Salaam, Tanzania.
Findings: A total of 270 E.coli and Klebsiella spp urinary pathogens from children and adults isolated from January
to March 2010 were included in the study. E. coli and Klebsiella spp isolates were tested for antimicrobial
susceptibility by the Clinical and Laboratory Standard Institute’s disc diffusion method. These isolates were further
screened for ESBL phenotype using cefotaxime and ceftazidime discs. Isolates with reduced sensitivity were
confirmed using ESBL E-test strips. Of 270 isolates, 138 (51.1%) were E. coli and 132 (48.9%) were Klebsiella spp. ESBL
was detected in 122 (45.2%) of all the isolates. ESBL- producing E. coli strains were significantly more resistance to
cotrimoxazole (90.7%), ciprofloxacin (46.3%) and nalidixic acid (61.6%) than strains that did not produce ESBL (p <
0.05). Similarly, ESBL- producing Klebsiella spp strains were significantly more resistance to cotrimoxazole (92.6%),
ciprofloxacin (25.0%), nalidixic acid (66.2%), and gentamicin (38.2%) than strains that did not produce ESBL (P <
0.05). Multi-drug resistance was found to be significantly (P < 0.05) more in ESBL producing isolates (90.5%) than
non ESBL producers (68.9%). The occurrence of ESBL was significantly higher among isolates from inpatients than
outpatients [95 (50.5%) vs. 27(32.9%)] (p = 0.008). The occurrence of ESBL was significantly higher among isolates
from children than in adults [84 (54.9%) vs. 38(32.5%)] (p < 0.001).
Conclusions: High prevalence of ESBL-producing E. coli and Klebsiella spp strains was found among inpatients and
children. Most of the ESBL- producing isolates were multi-drug resistant making available therapeutic choices
limited. We recommend continued antibiotic surveillance as well comprehensive multi-center studies to address
the emerging problem of ESBL-associated infections in order to preserve the continued usefulness of most
antimicrobial drugs. Further more conducting molecular studies will help to evaluate the various ESBL types.
Background
Urinary tract infection (UTI) is the second most com-
mon infectious presentation in community practice.
Worldwide, about 150 million people are diagnosed
with UTI each year, costing the global economy in
excess of 6 billion US dollars [1]. There have been sig-
nificant changes in the antimicrobial resistance patterns
of uropathogens over the years including resistance due
to extended spectrum beta lactamase (ESBL)-producing
pathogens [2-6]. The increasing prevalence of infections
caused by antibiotic-resistant bacteria makes empirical
treatment of these infections difficult [7]. Antibiotic
resistance varies according to geographic locations and
is directly proportional to the use and misuse of
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t a n c ei sc r u c i a la st h ec h a n g i n gr a t eo fa n t i b i o t i cr e s i s -
tance has a large impact on the treatment of UTI [3,4].
Production of ESBL is the most common amongst the
mechanisms of resistance to third generation cephalos-
porins in Gram-negative bacilli [8]. While there are
many published reports on ESBL-producing microor-
ganisms in developed and developing countries [5,6,9],
two previous studies which were done in 2005 con-
firmed the presence of ESBL-producing organisms in
nosocomial and blood stream infections in a tertiary
referral hospital in Dar es Salaam [10,11]. The current
study aimed to determine the prevalence of antimicro-
bial resistance and ESBL production among E. coli and
Klebsiella spp isolated from patients with UTI in a ter-
tiary hospital.
Materials and methods
Study design and setting
This was a cross-sectional study conducted at Muhimbili
National Hospital (MNH) in Dar es Salaam, Tanzania.
Urinary isolates collected from January to March 2010
were included in the study.
Bacterial isolates
Urine samples received in the Central Pathology Labora-
tory (CPL) were plated on cysteine lactose electrolytes
deficient (CLED) agar incubated at 37°C for 24 hours.
Ag r o w t ho f> 1 0
5 colony forming units per mL of one
type of organism was considered as significant bacter-
iuria. Identification of E. coli and Klebsiella spp isolates
was done by observing colonial morphology on CLED
medium. Lactose-fermenting colonies were further iden-
tified using standard biochemical tests as described pre-
viously [12].
Antibiotic susceptibility testing
E. coli and Klebsiella spp isolates were tested for antimi-
crobial susceptibility by the Clinical and Laboratory
Standards Institute’s disc diffusion method, was formerly
the National Committee for Clinical Laboratory Stan-
dards [13]. The following first and second line antibio-
tics were used in the testing: ceftazidime (30 μg),
cefotaxime (30 μg), cotrimoxazole (25 μg), ampicillin
(10 μg), gentamicin (15 μg), amikacin (30 μg), imipenem
(10 μg), ciprofloxacin (5 μg), nalidixic acid (30 μg), and
nitrofurantoin (300 μg). Multi-drug resistance was
defined as resistance to three or more different antimi-
crobial agents.
Detection of ESBL
E. coli and Klebsiella spp isolates were screened for ESBL
phenotype. Isolates with reduced susceptibilities to cefo-
taxime (zone diameter of <27 mm) and/or ceftazidime
(zone diameter of <22 mm) were provisionally regarded
as ESBL-producing pathogens according to guidelines for
laboratory detection of ESBL from Clinical and Labora-
tory Standards Institute [13]. ESBL E-test strips (Biomer-
ieux, Solna, Sweden) were used for confirmation of ESBL
production. Minimum inhibitory concentrations (MIC)
of cefotaxime and ceftazidime with and without clavula-
nic acid were determined. The inoculated plates were
incubated for 16-18 hours at 37°C.
ESBL results were read either as MIC values or obser-
vation of ‘phantom’ zones or deformation of inhibition
ellipses according to manufacturer instructions. Reduc-
tion of MIC by at least three two-fold dilutions in the
presence of clavulanic acid was indicative of ESBL pro-
duction. Deformation of ellipses or the presence of a
‘phantom’ zone was also indicative of ESBL production
even if the MIC ratio was <8 or could not be read. Iso-
lates were reported as having ESBL phenotype if one or
more of the ESBL E-tests were positive. E. coli ATCC
25922 was used as ESBL negative control and K. pneu-
moniae ATCC 700603 was used as ESBL positive refer-
ence strain.
Statistical analysis
Statistical Package for the Social Sciences (SPSS) version
17.0 was used for data analysis. Contingency table analy-
sis was done by a chi-square test or two-tailed Fisher’s
exact test where applicable. A p-value of less than 0.05
was considered as statistically significant.
Ethical considerations
The study was carried out in accordance with existing
ethical guidelines. Ethical clearance was obtained from
the Senate Research and Publications Committee of
Muhimbili University of Health and Allied Sciences, Dar
es Salaam.
Results
During the study period, a total of 270 E. coli and Kleb-
siella spp were isolated. The urinary pathogens were iso-
lated more from female (54.4%) than male (45.6%)
patients (Table 1). Of the total number of bacterial iso-
lates obtained 56.7% were from paediatric patients while
43.3% were from adults. Of the 270 isolates, 138 (51.1%)
were E. coli and 132 (48.9%) were Klebsiella spp.T h e r e
was significantly higher proportion of bacteria isolated
from inpatients (69.6%) than outpatients (30.4%) (p =
0.008).
The frequency of antimicrobial resistance for 11
selected antimicrobial agents against E. coli and Kleb-
siella spp UTI pathogens are summarized in Table 2
and 3. ESBL was detected in 122 (45.2%) of all the iso-
lates. Among E. coli isolates 39.1% were ESBL- produ-
cers. E. coli showed high rate of resistance was seen to
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Page 2 of 5ampicillin (96.4%), followed by cotrimoxazole (80.4%)
and amoxicillin/clavulanic acid (69.6%) (Table 2). Resis-
tance to cefotaxime and ceftazidime was 50.7% and
49.3%, respectively. E. coli showed showed least rate of
resistance to imipenem (6.5%). ESBL- producing E. coli
were significantly more resistant to cotri-moxazole
(90.7%), ciprofloxacin (46.3%) and nalidixic acid (61.6%)
than non-ESBL E. coli producing strains (p < 0.05).
Multi-drug resistance was significantly higher among
ESBL- producing E. coli strains than non-ESBL produ-
cing E. coli (87.0% vs. 54.8%) p < 0.001.
Among isolates of Klebsiella spp,5 1 . 1 %w e r eE S B L -
producers. Klebsiella spp showed high rate of resistance
to ampicillin (98.5%), followed by cotrimoxazole (82.6%)
and amoxicillin/clavulanic acid (78.0%) (Table 3). Resis-
tance to cefotaxime and ceftazidime was 65.9% and
65.9%, respectively. Klebsiella spp showed least rate of
resistance to imipenem (6.8%). ESBL- producing Kleb-
siella spp strains were significantly more resistant to
cotrimoxazole (92.6%), ciprofloxacin (25.0%), nalidixic
acid and gentamicin (38.2%) than non-ESBL producing
strains (p < 0.05). Other antimicrobial agents for which
ESBL-producing strains showed significant resistance
included cefotaxime (100%), ceftazidime (100%), cotri-
moxazole (92.6%), ciprofloxacin (25.0%), nalidixic acid
(66.2%) and gentamicin (38.2%) (p < 0.05). Multi-drug
resistance was significantly higher among ESBL- produ-
cing Klebsiella spp strains than non-ESBL producing
Klebsiella spp (82.4% vs. 35.9%) p < 0.001.
The occurrence of ESBL was found to be significantly
higher among isolates from inpatients than outpatients
[95 (50.5%) vs. 27(32.9%)] (p = 0.008). The rate of ESBL
production was also significantly higher among isolates
from children than in adults [84 (54.9%) vs. 38 (32.5%)]
(p < 0.001).
Discussion
Knowledge on local antimicrobial resistance trends
among urinary isolates is important not only in guiding
clinicians to prescribe appropriate antibiotics but also
for evidence based recommendations in empirical anti-
biotic treatment of UTI. The current study described
the antimicrobial resistance rates including detection of
ESBL among E. coli and Klebsiella spp urinary isolates
which are the predominant ESBL- producers.
In the current study the antimicrobial resistance rate
of both E. coli and Klebsiella spp isolates was high to
the first line antimicrobial agents such as ampicillin,
cotrimoxazole, and amoxicillin/clavulanic acid. High
resistance to first line drugs found in the current study
is similar to other studies in developing countries
[11,14,15]. The observation may be due to wide use of
Table 1 Distribution of bacteria isolates according
to patient age and sex, wards and bacterial species
(n = 270)
Characteristics Number Percentage
Age
Children 153 56.7
Adults 117 43.3
Sex
Male 123 45.6
Female 147 54.4
Wards
Out patients 82 30.4
In patients 188 69.6
Pathogens isolated
E. coli 138 51.1
Klebsiella spp 132 48.9
ESBL producing E. coli (n = 138) 54 39.1
ESBL producing Klebsiella spp (n = 132) 68 51.5
Table 2 Antimicrobial resistance of ESBL and non-ESBL producing E. coli in Dar es Salaam, Tanzania (n = 138)
Antibiotic Resistance
n (%)
ESBL- Producing
n=5 4
Non-ESBL producing
n=8 4
P-value*
Cefotaxime 70(50.7%) 50(92.6) 20(23.8) <0.001
Ceftazidime 68(49.3%) 51(94.4) 17(20.2) <0.001
Ampicillin 133(96.4%) 53(98.1) 80(95.2) 0.37
Amoxycillin/
clavulanic acid
96(69.6%) 39(72.2) 57(67.9) 0.6
Imipenem 9 (6.5%) 4(7.4) 5(0.001) 0.7
Amikacin 15(10.9%) 6(11.1) 9(10.7) 0.9
Gentamicin 53(38.4%) 26(48.1) 27(32.1) 0.06
Nalidixic acid 57(41.3%) 28(61.6) 29(34.5) 0.04
Ciprofloxacin 42(30.4%) 25(46.3) 17(20.2) 0.001
Nitrofurantoin 31(22.5%) 11(20.4) 20(23.8) 0.6
Cotrimoxazole 111(80.4%) 49(90.7) 62(73.8) 0.014
Multi drug resistance 93 (67.4%) 47(87.0) 46(54.8%) < 0.001
*P value is for a comparison of resistance among ESBL-producers with that among non-producers.
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Page 3 of 5these drugs empirically because they are relatively cheap
and also by being oral antibiotics they are easy to
administer. In addition, resistance to cotrimoxazole may
be due to the fact that this drug is widely used for pro-
phylaxis against opportunistic infections associated with
HIV whose prevalence in our setting is high. The high
level of resistance to amoxicillin/clavulanic acid is in
keeping with the previous report in the same hospital
[11] as well as studies conducted in other countries [16].
These findings suggest that beta-lactam/beta-lactamase
inhibitor combination may not be useful in our setting
for the treatment of UTI. A previous study has docu-
mented treatment failures due to the use of beta-lactam/
beta-lactamase inhibitor combinations for infections
caused by ESBL-producing organisms [17].
We demonstrated a high prevalence of ESBL produc-
tion by E. coli (39.1%) and by Klebsiella spp (51.5%)
urinary isolates at MNH. These findings are higher than
those reported five years ago in the same hospital
[10,11]. In the previous studies, 25% and 17% of E. coli
and Klebsiella spp, respectively, isolated from septicae-
mic patients [10] and 28.2% of enteric pathogens from
intensive care unit (ICU) patients [11] were ESBL-
producers. Several possible reasons may have contribu-
ted to the high prevalence of ESBL-producing urinary
isolates. Since UTI is relatively common, wide spread
use of broad-spectrum antibiotics due to inappropriate
prescribing practices are most likely. In addition, the
hospital does not perform routine screening of ESBL
production in clinical isolates and hence there are no
guidelines for isolation of patients carrying these ESBL-
producing strains which could have resulted in the
spread of these strains.
ESBL-producing E. coli and Klebsiella spp in this study
showed a significantly high rate of resistance to non-
beta lactam antibiotics. These findings are similar to
those reported by others [11,18-20]. This observation
may be explained by the fact that ESBL are plasmid-
mediated enzymes which are transferable between one
bacterium to another and such transferable plasmids
also code for resistance determinants to antimicrobial
agents other than beta-lactams [21]. ESBL-producing
E. coli and Klebsiella spp showed significantly high
resistance to ciprofloxacin. These findings are higher
than the resistance found by Blomberg et al in the same
study setting [10,11]. The increased resistance implies
that ciprofloxacin should be used with caution.
Our findings show that carbapenem are the most
effective and drug of choice against both ESBL and
non ESBL- producing E. coli and Klebsiella spp as
more than 90% of isolates were sensitive to imipenem.
Although imipenem showed high rate of sensitivity;
6.5% and 6.8% isolates of E. coli and Klebsiella spp,
respectively, were resistant. Reduced imipenem sus-
ceptibility has been described in E. coli with CTX-M-
type ESBL [22]. CTX-M type ESBL has been described
before in our settings [10,11], which in part could
explain the observation in the current study. Therefore
further studies are needed for molecular characteriza-
tion of ESBL isolates circulating in our setting. With
sensitivity rate of 79% for ESBL-producing isolates
nitrofurantoin might be the only useful oral antibiotic
in the treatment of UTI in the local setting, at least in
a tertiary health facility.
There was significantly higher proportion of ESBL-
producing isolates among isolates from in-patients than
out-patients (p < 0.05). This finding is similar to that
observed by Khanfar et al [16] and points to the possibi-
lity of nosocomial acquisition of UTI due to ESBL
pathogens. These findings have significant implications
for empirical management of patients with UTI using
third generation cephalosporins.
Table 3 Antimicrobial resistance of ESBL and non-ESBL producing Klebsiella spp in Dar es Salaam, Tanzania (n = 138)
Antibiotic Resistance
n (%)
ESBL- Producing
n=6 8
Non-ESBL producing
n=6 4
P-value*
Cefotaxime 87(65.9%) 68(100) 19(29.7) <0.001
Ceftazidime 87(65.9%) 68(100) 19(29.7) <0.001
Ampicillin 130(98.5%) 67(98.5) 63(98.4) 0.9
Amoxicillin/
clavulanic acid
103(78.0%) 57(83.8) 46(71.9) 0.09
Imipenem 9(6.8%) 6(8.8) 3(4.7) 0.2
Amikacin 28(21.2%) 17(25.0) 11(17.2) 0.2
Gentamicin 38(28.8%) 26(38.2) 12(18.8) 0.008
Nalidixic acid 65(49.2%) 45(66.2) 20(31.2) <0.001
Ciprofloxacin 25(18.9%) 17(25.0) 18(28.1) 0.04
Nitrofurantoin 24(18.2%) 14(20.6) 11(17.2) 0.5
Cotrimoxazole 109(82.6%) 63(92.6) 46(71.9) 0.001
Multi drug resistance 79(59.8%) 56(82.4) 23(35.9) <0.001
*P value is for a comparison of resistance among ESBL-producers with that among non-Producers.
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been reported to be associated with risk factors such as
age. In the current study, ESBL production was signifi-
cantly higher in children (68.9%) than adults (31.1%)
(p < 0.05). These findings compare well with those
reported elsewhere [18,23].
Conclusions
High prevalence of ESBL-producing E. coli and Klebsiella
spp strains was found among inpatients and children.
Most of the ESBL- producing isolates were multi-drug
resistant making available therapeutic choices limited. We
recommend continued antibiotic surveillance as well
comprehensive multi-center studies to address the emer-
ging problem of ESBL-associated infections in order to
preserve the continued usefulness of most antimicrobial
drugs. Further more conducting molecular studies will
help to evaluate the various ESBL types.
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